Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Morpholines"" wg kryterium: Temat


Tytuł:
Activity of amorolfine or ciclopirox in combination with terbinafine against pathogenic fungi in onychomycosis-Results of an in vitro investigation.
Autorzy:
Schaller M; Department of Dermatology, Eberhard-Karls University Hospital, Tübingen, Germany.
Walker B; Department of Dermatology, Eberhard-Karls University Hospital, Tübingen, Germany.
Nabhani S; Medical and Regulatory Department, Galderma Laboratorium GmbH, Düsseldorf, Germany.
Odon A; Department of Dermatology, Eberhard-Karls University Hospital, Tübingen, Germany.
Riel S; Department of Dermatology, Eberhard-Karls University Hospital, Tübingen, Germany.
Jäckel A; Medical and Regulatory Department, Galderma Laboratorium GmbH, Düsseldorf, Germany.
Pokaż więcej
Źródło:
Mycoses [Mycoses] 2024 Mar; Vol. 67 (3), pp. e13710.
Typ publikacji:
Journal Article
MeSH Terms:
Onychomycosis*/drug therapy
Onychomycosis*/microbiology
Morpholines*
Humans ; Terbinafine/pharmacology ; Terbinafine/therapeutic use ; Ciclopirox/pharmacology ; Ciclopirox/therapeutic use ; Antifungal Agents/therapeutic use ; Naphthalenes
Czasopismo naukowe
Tytuł:
A protectin DX (PDX) analog with in vitro activity against influenza A(H1N1) viruses.
Autorzy:
Fortin N; Research Center in Infectious Diseases, CHU de Québec-Université Laval, Quebec City, Canada.
Hénaut M; Research Center in Infectious Diseases, CHU de Québec-Université Laval, Quebec City, Canada.
Goyette N; Research Center in Infectious Diseases, CHU de Québec-Université Laval, Quebec City, Canada.
Maltais R; Medicinal Chemistry Platform, CHU de Québec-Université Laval, Quebec City, Canada.
Sancéau JY; Medicinal Chemistry Platform, CHU de Québec-Université Laval, Quebec City, Canada.
Marette A; Medicinal Chemistry Platform, CHU de Québec-Université Laval, Quebec City, Canada.
Poirier D; Medicinal Chemistry Platform, CHU de Québec-Université Laval, Quebec City, Canada.
Abed Y; Research Center in Infectious Diseases, CHU de Québec-Université Laval, Quebec City, Canada.
Boivin G; Research Center in Infectious Diseases, CHU de Québec-Université Laval, Quebec City, Canada.
Pokaż więcej
Źródło:
Journal of medical virology [J Med Virol] 2024 Mar; Vol. 96 (3), pp. e29484.
Typ publikacji:
Journal Article
MeSH Terms:
Influenza A Virus, H1N1 Subtype*
Influenza, Human*/drug therapy
Influenza A virus*
Triazines*
Dibenzothiepins*
Docosahexaenoic Acids*
Morpholines*
Pyridones*
Animals ; Humans ; Oseltamivir/pharmacology ; Oseltamivir/therapeutic use ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Anti-Inflammatory Agents/therapeutic use ; Drug Resistance, Viral ; Neuraminidase
Czasopismo naukowe
Tytuł:
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Autorzy:
Parisi A; Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy. Electronic address: .
Delaunay B; Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy; Digestive Oncology Department, Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, France.
Pinterpe G; Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy.
Hollebecque A; Département d'Innovation Thérapeutique et Essais précoces (DITEP), Gustave Roussy, Villejuif Cedex, France.
Blanc JF; Oncology Digestive Unit, Hôpital haut-Lévêque, CHU Bordeaux France, France.
Bouattour M; Liver Oncology and Therapeutic Innovation Functional Unit, Beaujon Hospital APHP, Clichy, France.
Assenat E; Medical oncology, ICM - Institut du Cancer de Montpellier, Montpellier Cedex, France.
Ben Abdelghani M; Oncology Department, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
Sarabi M; Medical Oncology, Centre Léon Bérard, Lyon, GI Oncology Department, France; GI Oncology Department, Hôpital privé Jean Mermoz, Lyon, France.
Niger M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Venezian 1, 20133 Milan, Italy.
Vivaldi C; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
Mandalà M; Unit of Medical Oncology, University of Perugia, Perugia, Italy.
Palloni A; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Bensi M; Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Italy; Università Cattolica del Sacro Cuore, Roma, Italy.
Garattini SK; Department of Oncology, Academic Hospital of Udine ASUFC, Piazzale Santa Maria della Misericordia 15, Udine, UD 33100, Italy.
Tougeron D; Université de Poitiers, Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France.
Combe P; Medical Oncology, CORT37, Pôle Santé Léonard de Vinci, Chambray-lès-Tours, France.
Salati M; Division of Oncology, Department of Oncology and Hematology, University Hospital Modena, Modena Cancer Centre, Via del Pozzo 71, 41125 Modena, Italy; Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Rimini M; Vita-Salute University San Raffaele, Milan, Italy; Department of Oncology, IRCCS San Raffaele Hospital, via Olgettina N. 60, Milan 20132, Italy.
Cella CA; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO IRCCS, Via Ripamonti 435, Milan, Italy.
Tucci M; Department of Interdisciplinary Medicine, Oncology Unit, University of Bari 'Aldo Moro', P.za Giulio Cesare, 11, 70124, Bari, Italy.
Diana A; UOC Oncologia - Ospedale del Mare, Naples.
Mori E; Department of Medical Oncology, New Hospital of Prato S. Stefano, 59100 Prato, Italy.
Longarini R; Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Artru P; GI Oncology Department, Hôpital privé Jean Mermoz, Lyon, France.
Roth G; Univ. Grenoble Alpes / Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes / Institute for Advanced Biosciences, CNRS UMR 5309-INSERM, U1209, France.
Evesque L; Medical Oncology Department, Centre Antoine-Lacassagne, Nice, France.
Vienne A; Oncology Department, CHU Sud Réunion, Saint Pierre, France.
Turpin A; Medical Oncology Department, Hopital Claude Huriez, Lille, France.
Hiret S; Oncology Department, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, France.
Bourgeois V; Digestive Oncology, Hopital duchenne Boulogne-sur-Mer, France.
Herve C; Digestive Oncology, Groupe Hospitalier Mutualiste, Grenoble.
Paulon R; Medical Oncology, Clinique du Sidobre, Castres, France.
Stacoffe M; Medical Oncology, CHRU Hopitaux de Tours - Hopital Bretonneau, Tours Cedex, France.
Malka D; Medical Oncology, Institut Mutualiste Montsouris, Paris, France.
Neuzillet C; GI Oncology, Medical Oncology Department, Curie Institute, Paris, France.
Edeline J; Medical Oncology Department, Centre Eugene - Marquis, Rennes, France.
Lievre A; Department of Gastroenterology, CHU de Rennes - Hopital Pontchaillou, Rennes Cedex, France.
Guimbaud R; Digestive Oncology Department, Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, France.
Chapda MCP; MeDatas, CIC (Centre d'Investigation Clinique), CHU Toulouse, Toulouse, France.
Rimassa L; Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy.
Giampieri R; Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy.
Valle J; Cholangiocarcinoma Foundation, Salt Lake City, Utah, USA; Division of Cancer Sciences, University of Manchester, Manchester, UK.
Berardi R; Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy.
Fares N; Digestive Oncology Department, Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, France.
Pokaż więcej
Źródło:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Mar; Vol. 200, pp. 113587. Date of Electronic Publication: 2024 Feb 06.
Typ publikacji:
Journal Article
MeSH Terms:
Cholangiocarcinoma*/drug therapy
Cholangiocarcinoma*/genetics
Cholangiocarcinoma*/pathology
Bile Duct Neoplasms*/drug therapy
Bile Duct Neoplasms*/genetics
Bile Duct Neoplasms*/pathology
Morpholines*
Pyrimidines*
Pyrroles*
Humans ; Female ; Middle Aged ; Male ; Retrospective Studies ; Cohort Studies ; Bile Ducts, Intrahepatic/pathology ; Receptor, Fibroblast Growth Factor, Type 2/genetics
Czasopismo naukowe
Tytuł:
Pythium insidiosum: In vitro oomicidal evaluation of telithromycin and interactions with azithromycin and amorolfine hydrochloride.
Autorzy:
Ianiski LB; Departamento de Medicina Veterinária Preventiva, Laboratório de Saúde Única, Programa de Pós-graduação em Ciências Farmacêuticas (PPGCF) e de Medicina Veterinária (PPGMV), Centro de Ciências Rurais, Universidade Federal de Santa Maria (UFSM), Av. Roraima N° 1000, Prédio 44, sala 5132, CEP, Santa Maria, RS 97105-900, Brazil.
Maciel AF; Departamento de Medicina Veterinária Preventiva, Laboratório de Saúde Única, Programa de Pós-graduação em Ciências Farmacêuticas (PPGCF) e de Medicina Veterinária (PPGMV), Centro de Ciências Rurais, Universidade Federal de Santa Maria (UFSM), Av. Roraima N° 1000, Prédio 44, sala 5132, CEP, Santa Maria, RS 97105-900, Brazil.
Colla ACN; Departamento de Medicina Veterinária Preventiva, Laboratório de Saúde Única, Programa de Pós-graduação em Ciências Farmacêuticas (PPGCF) e de Medicina Veterinária (PPGMV), Centro de Ciências Rurais, Universidade Federal de Santa Maria (UFSM), Av. Roraima N° 1000, Prédio 44, sala 5132, CEP, Santa Maria, RS 97105-900, Brazil.
Braga CQ; Instituto de Biologia, Universidade Federal de Pelotas (UFPel), Pelotas, RS, Brazil.
Sangioni LA; Departamento de Medicina Veterinária Preventiva, Laboratório de Saúde Única, Programa de Pós-graduação em Ciências Farmacêuticas (PPGCF) e de Medicina Veterinária (PPGMV), Centro de Ciências Rurais, Universidade Federal de Santa Maria (UFSM), Av. Roraima N° 1000, Prédio 44, sala 5132, CEP, Santa Maria, RS 97105-900, Brazil.
Pal M; Narayan Consultancy on Veterinary Public Health and Microbiology, Bharuch, India.
Pereira DIB; Instituto de Biologia, Universidade Federal de Pelotas (UFPel), Pelotas, RS, Brazil.
Santurio JM; Departamento de Medicina Veterinária Preventiva, Laboratório de Saúde Única, Programa de Pós-graduação em Ciências Farmacêuticas (PPGCF) e de Medicina Veterinária (PPGMV), Centro de Ciências Rurais, Universidade Federal de Santa Maria (UFSM), Av. Roraima N° 1000, Prédio 44, sala 5132, CEP, Santa Maria, RS 97105-900, Brazil.
Botton SA; Departamento de Medicina Veterinária Preventiva, Laboratório de Saúde Única, Programa de Pós-graduação em Ciências Farmacêuticas (PPGCF) e de Medicina Veterinária (PPGMV), Centro de Ciências Rurais, Universidade Federal de Santa Maria (UFSM), Av. Roraima N° 1000, Prédio 44, sala 5132, CEP, Santa Maria, RS 97105-900, Brazil. Electronic address: .
Pokaż więcej
Źródło:
Journal de mycologie medicale [J Mycol Med] 2024 Mar; Vol. 34 (1), pp. 101460. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Journal Article
MeSH Terms:
Ketolides*/pharmacology
Ketolides*/therapeutic use
Pythium*
Pythiosis*/drug therapy
Pythiosis*/microbiology
Morpholines*
Animals ; Humans ; Antifungal Agents/pharmacology ; Azithromycin/pharmacology ; Azithromycin/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Mammals
Czasopismo naukowe
Tytuł:
Somatic and anxiety-like behaviors in male and female rats during withdrawal from the non-selective cannabinoid agonist WIN 55,212-2.
Autorzy:
Brewer AL; Department of Pharmacology, University of Minnesota, Minneapolis, MN, United States of America; Medical Discovery Team on Addiction, University of Minnesota, Minneapolis, MN, United States of America. Electronic address: .
Felter CE; Department of Pharmacology, University of Minnesota, Minneapolis, MN, United States of America; Medical Discovery Team on Addiction, University of Minnesota, Minneapolis, MN, United States of America.
Sternitzky AR; Department of Pharmacology, University of Minnesota, Minneapolis, MN, United States of America; Medical Discovery Team on Addiction, University of Minnesota, Minneapolis, MN, United States of America.
Spencer SM; Department of Pharmacology, University of Minnesota, Minneapolis, MN, United States of America; Medical Discovery Team on Addiction, University of Minnesota, Minneapolis, MN, United States of America.
Pokaż więcej
Źródło:
Pharmacology, biochemistry, and behavior [Pharmacol Biochem Behav] 2024 Mar; Vol. 236, pp. 173707. Date of Electronic Publication: 2024 Jan 18.
Typ publikacji:
Journal Article
MeSH Terms:
Cannabinoids*/pharmacology
Substance Withdrawal Syndrome*
Morpholines*
Naphthalenes*
Benzoxazines*
Rats ; Female ; Animals ; Male ; Cannabinoid Receptor Agonists/pharmacology ; Rimonabant/pharmacology ; Dronabinol/adverse effects ; Piperidines/pharmacology ; Pyrazoles ; Rats, Long-Evans ; Anxiety/chemically induced ; Calcium Carbonate
Czasopismo naukowe
Tytuł:
Using mechanism-based combinations of H 2 S-donors to maximize the cardioprotective action of H 2 S.
Autorzy:
Ravani S; Center of Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.; Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Chatzianastasiou A; Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Papapetropoulos A; Center of Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. .; Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece. .
Pokaż więcej
Źródło:
Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2024 Mar; Vol. 397 (3), pp. 1853-1864. Date of Electronic Publication: 2023 Sep 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hydrogen Sulfide*/pharmacology
Hydrogen Sulfide*/therapeutic use
Hydrogen Sulfide*/metabolism
Reperfusion Injury*
Morpholines*
Organothiophosphorus Compounds*
Mice ; Animals ; Mice, Inbred C57BL ; Ischemia ; Infarction ; Obesity
Czasopismo naukowe
Tytuł:
Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis.
Autorzy:
Shiraishi C; Department of Pharmacy, Mie University Hospital, Mie, Japan; Department of Clinical Pharmaceutics, Division of Clinical Medical Science, Mie University Graduate School of Medicine, Mie, Japan.
Kato H; Department of Pharmacy, Mie University Hospital, Mie, Japan; Department of Clinical Pharmaceutics, Division of Clinical Medical Science, Mie University Graduate School of Medicine, Mie, Japan; Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan.
Hagihara M; Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan; Department of Molecular Epidemiology and Biomedical Sciences, Aichi Medical University Hospital, Aichi, Japan.
Asai N; Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan.
Iwamoto T; Department of Pharmacy, Mie University Hospital, Mie, Japan; Department of Clinical Pharmaceutics, Division of Clinical Medical Science, Mie University Graduate School of Medicine, Mie, Japan.
Mikamo H; Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan. Electronic address: .
Pokaż więcej
Źródło:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2024 Mar; Vol. 30 (3), pp. 242-249. Date of Electronic Publication: 2023 Oct 20.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Influenza, Human*/drug therapy
Thiepins*/adverse effects
Orthomyxoviridae Infections*/drug therapy
Dibenzothiepins*
Morpholines*
Pyridones*
Triazines*
Humans ; Oseltamivir/adverse effects ; Retrospective Studies ; Antiviral Agents/adverse effects ; Oxazines ; Pyridines/pharmacology ; Treatment Outcome ; RNA, Viral
Czasopismo naukowe
Tytuł:
Isothiocyanates Potentiate Tazemetostat-Induced Apoptosis by Modulating the Expression of Apoptotic Genes, Members of Polycomb Repressive Complex 2, and Levels of Tri-Methylating Lysine 27 at Histone 3 in Human Malignant Melanoma Cells.
Autorzy:
Anestopoulos I; Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, Ayios Dometios, Nicosia 2371, Cyprus.
Paraskevaidis I; Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, Ayios Dometios, Nicosia 2371, Cyprus.
Kyriakou S; Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, Ayios Dometios, Nicosia 2371, Cyprus.
Giova LE; Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, Ayios Dometios, Nicosia 2371, Cyprus.
Trafalis DT; Laboratory of Pharmacology, Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.
Botaitis S; Department of Surgery, School of Medicine, University Hospital, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Franco R; School of Veterinary Medicine & Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.; Redox Biology Centre, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.
Pappa A; Department of Molecular Biology & Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Panayiotidis MI; Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, Ayios Dometios, Nicosia 2371, Cyprus.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 27; Vol. 25 (5). Date of Electronic Publication: 2024 Feb 27.
Typ publikacji:
Journal Article
MeSH Terms:
Histones*/metabolism
Melanoma*
Benzamides*
Biphenyl Compounds*
Morpholines*
Pyridones*
Humans ; Polycomb Repressive Complex 2/genetics ; Lysine/metabolism ; Enhancer of Zeste Homolog 2 Protein/genetics ; Apoptosis
Czasopismo naukowe
Tytuł:
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Autorzy:
Hardaker EL; Oncology R&D, AstraZeneca, Cambridge, UK.
Sanseviero E; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Karmokar A; Oncology R&D, AstraZeneca, Cambridge, UK.
Taylor D; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Milo M; Oncology R&D, AstraZeneca, Cambridge, UK.
Michaloglou C; Oncology R&D, AstraZeneca, Cambridge, UK.
Hughes A; Oncology R&D, AstraZeneca, Cambridge, UK.
Mai M; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
King M; Oncology R&D, AstraZeneca, Cambridge, UK.
Solanki A; Oncology R&D, AstraZeneca, Cambridge, UK.
Magiera L; Oncology R&D, AstraZeneca, Cambridge, UK.
Miragaia R; Oncology R&D, AstraZeneca, Cambridge, UK.
Kar G; Oncology R&D, AstraZeneca, Cambridge, UK.
Standifer N; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.; Tempest Therapeutics, Brisbane, CA, USA.
Surace M; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Gill S; Oncology R&D, AstraZeneca, Cambridge, UK.
Peter A; Oncology R&D, AstraZeneca, Cambridge, UK.
Talbot S; Oncology R&D, AstraZeneca, Cambridge, UK.
Tohumeken S; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Fryer H; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Mostafa A; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Mulgrew K; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Lam C; Oncology R&D, AstraZeneca, Cambridge, UK.
Hoffmann S; Imaging and Data Analytics, AstraZeneca, Cambridge, UK.
Sutton D; Imaging and Data Analytics, AstraZeneca, Cambridge, UK.
Carnevalli L; Oncology R&D, AstraZeneca, Cambridge, UK.
Calero-Nieto FJ; Oncology R&D, AstraZeneca, Cambridge, UK.
Jones GN; Oncology R&D, AstraZeneca, Cambridge, UK.
Pierce AJ; Oncology R&D, AstraZeneca, Cambridge, UK.; Crescendo Biologics Limited, Cambridge, UK.
Wilson Z; Oncology R&D, AstraZeneca, Cambridge, UK.
Campbell D; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Nyoni L; Oncology R&D, AstraZeneca, Cambridge, UK.
Martins CP; Oncology R&D, AstraZeneca, Cambridge, UK.
Baker T; CPSS AST, AstraZeneca, Cambridge, UK.
Serrano de Almeida G; CPSS AST, AstraZeneca, Cambridge, UK.
Ramlaoui Z; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Bidar A; CPSS, Imaging, AstraZeneca, Gothenburg, Sweden.
Phillips B; Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
Boland J; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Iyer S; Oncology R&D, AstraZeneca, Boston, MA, USA.
Barrett JC; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Loembé AB; Early Clinical Development, AstraZeneca, Oss, the Netherlands.
Fuchs SY; Department of Biomedical Sciences, School of Veterinary Medicine University of Pennsylvania, Philadelphia, PA, 19104, USA.
Duvvuri U; UPMC Department of Otolaryngology and UPMC Hillman Cancer Center, 200 Lothrop St. Suite 500, Pittsburg, PA, 15213, USA.
Lou PJ; National Taiwan University Hospital, No. 7, Chung Shan S. Rd. (Zhongshan S. Rd.), Zhongzheng Dist., Taipei City, 10002, Taiwan.
Nance MA; VA Pittsburgh Healthcare System, University Drive C, Pittsburg, PA, 15240, USA.
Gomez Roca CA; Institut Claudius Regaud-Cancer Comprehensive Center, 1 Avenue Irene Joliot-Curie, IUCT-O, Toulouse, 31059 Cedex 9, France.
Cadogan E; Oncology R&D, AstraZeneca, Cambridge, UK.
Critichlow SE; Oncology R&D, AstraZeneca, Cambridge, UK.
Fawell S; Oncology R&D, AstraZeneca, Boston, MA, USA.
Cobbold M; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.
Dean E; Oncology R&D, AstraZeneca, Cambridge, UK.
Valge-Archer V; Oncology R&D, AstraZeneca, Cambridge, UK.
Lau A; Oncology R&D, AstraZeneca, Cambridge, UK.
Gabrilovich DI; Oncology R&D, AstraZeneca, Gaithersburg, MD, 20878, USA. .
Barry ST; Oncology R&D, AstraZeneca, Cambridge, UK. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2024 Feb 24; Vol. 15 (1), pp. 1700. Date of Electronic Publication: 2024 Feb 24.
Typ publikacji:
Journal Article
MeSH Terms:
CD8-Positive T-Lymphocytes*
Neoplasms*
Indoles*
Morpholines*
Pyrimidines*
Sulfonamides*
Humans ; Animals ; Mice ; B7-H1 Antigen ; Tumor Microenvironment ; Cell Line, Tumor ; Immunotherapy ; Disease Models, Animal ; Ataxia Telangiectasia Mutated Proteins
Czasopismo naukowe
Tytuł:
Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2).
Autorzy:
Chen Z; Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, Jiangsu Provincial Key Lab for the Chemistry and Utilization of Agro-Forest Biomass, Jiangsu Key Lab of Biomass-Based Green Fuels and Chemicals, International Innovation Center for Forest Chemicals and Materials, College of Chemical Engineering, Nanjing Forestry University, Nanjing, Jiangsu 210037, China.; Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.
Chen J; Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Rd, Atlanta, Georgia 30322, United States.; Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.
Mori W; Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Yi Y; Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, Jiangsu Provincial Key Lab for the Chemistry and Utilization of Agro-Forest Biomass, Jiangsu Key Lab of Biomass-Based Green Fuels and Chemicals, International Innovation Center for Forest Chemicals and Materials, College of Chemical Engineering, Nanjing Forestry University, Nanjing, Jiangsu 210037, China.
Rong J; Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Rd, Atlanta, Georgia 30322, United States.; Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.
Li Y; Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Rd, Atlanta, Georgia 30322, United States.; Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.
Leon ERC; Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States.
Shao T; Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.
Song Z; Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Rd, Atlanta, Georgia 30322, United States.
Yamasaki T; Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Ishii H; Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Zhang Y; Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Kokufuta T; Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Hu K; Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Xie L; Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Josephson L; Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.
Van R; Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States.
Shao Y; Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States.
Factor S; Jean and Paul Amos Parkinson's Disease and Movement Disorder Program, Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, United States.
Zhang MR; Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Liang SH; Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Rd, Atlanta, Georgia 30322, United States.; Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2024 Feb 22; Vol. 67 (4), pp. 2559-2569. Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:
Journal Article
MeSH Terms:
Pyrimidines*
Parkinson Disease*/metabolism
Morpholines*
Nitriles*
Mice ; Animals ; Humans ; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/genetics ; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/metabolism ; Leucine ; Positron-Emission Tomography/methods ; Mutation
Czasopismo naukowe
Tytuł:
Discovery of a Macrocyclic Influenza Cap-Dependent Endonuclease Inhibitor.
Autorzy:
Feng J; WuXi AppTec Co., Ltd., Shanghai 200131, China.
Guo F; WuXi AppTec Co., Ltd., Shanghai 200131, China.
Li P; WuXi AppTec Co., Ltd., Shanghai 200131, China.
Zhang J; Pharmaceutical Research Institute, Cisen Pharmaceutical Co., Ltd., Jining 272000, China.
Jiang K; WuXi AppTec Co., Ltd., Shanghai 200131, China.
Zhu Z; WuXi AppTec Co., Ltd., Shanghai 200131, China.
Yin S; WuXi AppTec Co., Ltd., Shanghai 200131, China.
Lin X; WuXi AppTec Co., Ltd., Shanghai 200131, China.
Lin F; WuXi AppTec Co., Ltd., Shanghai 200131, China.
Xiao F; WuXi AppTec Co., Ltd., Shanghai 200131, China.
Xue X; Pharmaceutical Research Institute, Cisen Pharmaceutical Co., Ltd., Jining 272000, China.
He H; WuXi AppTec Co., Ltd., Shanghai 200131, China.
Chen S; WuXi AppTec Co., Ltd., Shanghai 200131, China.
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2024 Feb 22; Vol. 67 (4), pp. 2570-2583. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Influenza, Human*/drug therapy
Thiepins*/pharmacology
Thiepins*/therapeutic use
Dibenzothiepins*
Morpholines*
Humans ; Oxazines/pharmacology ; Pyridines/pharmacology ; Endonucleases ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Pyridones/pharmacology ; Pyridones/therapeutic use ; Triazines/pharmacology ; Triazines/therapeutic use
Czasopismo naukowe
Tytuł:
Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
Autorzy:
Park S; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Kim YJ; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Min YJ; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
Mortimer PGS; R&D Oncology, AstraZeneca, Cambridge, UK.
Kim HJ; External R&D, R&D Oncology, AstraZeneca, Seoul, Korea.
Smith SA; R&D Oncology, AstraZeneca, Cambridge, UK.
Dean E; R&D Oncology, AstraZeneca, Cambridge, UK.
Jung HA; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Sun JM; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Park WY; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Ahn JS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Lee SH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Park K; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Cancer [Cancer] 2024 Feb 15; Vol. 130 (4), pp. 541-552. Date of Electronic Publication: 2023 Oct 16.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Small Cell Lung Carcinoma*/drug therapy
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/chemically induced
Ovarian Neoplasms*/drug therapy
Pyrimidines*
Piperazines*
Sulfonamides*
Indoles*
Morpholines*
Humans ; Female ; Treatment Outcome ; Phthalazines/adverse effects
Czasopismo naukowe
Tytuł:
Structural Studies of Inhibitors with Clinically Relevant Influenza Endonuclease Variants.
Autorzy:
Kohlbrand AJ; Department of Chemistry and Biochemistry, University of California, La Jolla, California 92093, United States.
Stokes RW; Department of Chemistry and Biochemistry, University of California, La Jolla, California 92093, United States.
Sankaran B; The Berkeley Center for Structural Biology, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States.
Cohen SM; Department of Chemistry and Biochemistry, University of California, La Jolla, California 92093, United States.
Pokaż więcej
Źródło:
Biochemistry [Biochemistry] 2024 Feb 06; Vol. 63 (3), pp. 264-272. Date of Electronic Publication: 2024 Jan 08.
Typ publikacji:
Journal Article
MeSH Terms:
Influenza, Human*
Thiepins*/pharmacology
Thiepins*/therapeutic use
Dibenzothiepins*
Morpholines*
Humans ; Oxazines ; Pyridines/pharmacology ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Endonucleases/genetics ; Pyridones/therapeutic use ; Oseltamivir/pharmacology ; Oseltamivir/therapeutic use ; Zanamivir/therapeutic use ; Triazines/pharmacology ; Triazines/therapeutic use
Czasopismo naukowe
Tytuł:
The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma.
Autorzy:
Xie L; Musculoskeletal Tumor Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, P. R. China.
Sun X; Musculoskeletal Tumor Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, P. R. China.
Xu J; Musculoskeletal Tumor Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, P. R. China.
Liang X; Musculoskeletal Tumor Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, P. R. China.
Liu K; Musculoskeletal Tumor Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, P. R. China.
Sun K; Pathology Department, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, P. R. China.
Yang R; Musculoskeletal Tumor Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, P. R. China.
Tang X; Musculoskeletal Tumor Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, P. R. China. .
Guo W; Musculoskeletal Tumor Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, P. R. China.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 03; Vol. 24 (1), pp. 172. Date of Electronic Publication: 2024 Feb 03.
Typ publikacji:
Journal Article
MeSH Terms:
Sarcoma*/pathology
Biphenyl Compounds*
Benzamides*
Morpholines*
Quinolines*
Indoles*
Pyridones*
Humans ; Irinotecan/therapeutic use ; Vincristine/therapeutic use ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
MHY1485 promotes adriamycin sensitivity in HepG2 cells by inhibiting autophagy.
Autorzy:
Guo J; Department of Medical Oncology, He Xian Memorial Affiliated Hospital of Southern Medical University, Guangzhou, China. .; Department of Medical Oncology, Panyu Maternal and Child Care Service Center of Guangzhou, Guangzhou, China. .
Lei Y; Department of Medical Oncology, He Xian Memorial Affiliated Hospital of Southern Medical University, Guangzhou, China.; Department of Medical Oncology, Panyu Maternal and Child Care Service Center of Guangzhou, Guangzhou, China.
Liu L; Department of Medical Oncology, He Xian Memorial Affiliated Hospital of Southern Medical University, Guangzhou, China.; Department of Medical Oncology, Panyu Maternal and Child Care Service Center of Guangzhou, Guangzhou, China.
Wen Z; Department of Medical Oncology, He Xian Memorial Affiliated Hospital of Southern Medical University, Guangzhou, China.; Department of Medical Oncology, Panyu Maternal and Child Care Service Center of Guangzhou, Guangzhou, China.
Zhang B; Department of Medical Oncology, He Xian Memorial Affiliated Hospital of Southern Medical University, Guangzhou, China.; Department of Medical Oncology, Panyu Maternal and Child Care Service Center of Guangzhou, Guangzhou, China.
Fang J; Department of Medical Oncology, He Xian Memorial Affiliated Hospital of Southern Medical University, Guangzhou, China.; Department of Medical Oncology, Panyu Maternal and Child Care Service Center of Guangzhou, Guangzhou, China.
Liang G; Department of Medical Oncology, He Xian Memorial Affiliated Hospital of Southern Medical University, Guangzhou, China.; Department of Medical Oncology, Panyu Maternal and Child Care Service Center of Guangzhou, Guangzhou, China.
Guo Q; Department of Medical Oncology, He Xian Memorial Affiliated Hospital of Southern Medical University, Guangzhou, China.; Department of Medical Oncology, Panyu Maternal and Child Care Service Center of Guangzhou, Guangzhou, China.
Peng J; Department of Medical Oncology, He Xian Memorial Affiliated Hospital of Southern Medical University, Guangzhou, China.; Department of Medical Oncology, Panyu Maternal and Child Care Service Center of Guangzhou, Guangzhou, China.
Pokaż więcej
Źródło:
Functional & integrative genomics [Funct Integr Genomics] 2024 Feb 02; Vol. 24 (1), pp. 22. Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/metabolism
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/metabolism
Morpholines*
Triazines*
Humans ; Doxorubicin/pharmacology ; Hep G2 Cells ; Apoptosis ; TOR Serine-Threonine Kinases/genetics ; TOR Serine-Threonine Kinases/metabolism ; Autophagy ; Cell Proliferation ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Pharmacokinetics, Safety, and Tolerability of a Single 5-Day Treatment of Tirbanibulin Ointment 1% in 100 cm : A Phase 1 Maximal-Use Trial in Patients with Actinic Keratosis.
Autorzy:
DuBois J; DermResearch, Inc., Austin, TX, USA.
Jones TM; J&S Studies, Inc., College Station, TX, USA.
Lee MS; Progressive Clinical Research, San Antonio, TX, USA.
Falqués M; Almirall, Sant Feliu de Llobregat, Spain.
Kiyasova V; Almirall, Sant Feliu de Llobregat, Spain.
Jiménez G; Almirall, Barcelona, Spain.
Otero R; Almirall, Sant Feliu de Llobregat, Spain.
Jansat JM; Almirall, Sant Feliu de Llobregat, Spain.
Aubets J; Almirall, Sant Feliu de Llobregat, Spain.
Forconi RJ; International Clinical Research - US, LLC, Sanford, FL, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2024 Feb; Vol. 13 (2), pp. 208-218. Date of Electronic Publication: 2024 Jan 07.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Keratosis, Actinic*/drug therapy
Keratosis, Actinic*/diagnosis
Acetamides*
Morpholines*
Pyridines*
Adult ; Humans ; Ointments ; Treatment Outcome ; Europe
Czasopismo naukowe
Tytuł:
Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study.
Autorzy:
Kuwana M; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Japan.
Ito T; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Kowata S; Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.
Hatta Y; Department of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan.
Fujimaki K; Department of Hematology, Fujisawa City Hospital, Fujisawa, Japan.
Naito K; Department of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan.
Kurahashi S; Department of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan.
Kagoo T; Division of Hematology, Department of Internal Medicine, National Hospital Organization Tokyo Medical Center, Meguro-ku, Japan.
Tanimoto K; Hematology and Oncology Division, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
Saotome S; Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.
Tomiyama Y; Department of Blood Transfusion, Osaka University Hospital, Suita, Japan.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2024 Feb; Vol. 99 (2), pp. E55-E59. Date of Electronic Publication: 2024 Jan 02.
Typ publikacji:
Randomized Controlled Trial; Letter
MeSH Terms:
Purpura, Thrombocytopenic, Idiopathic*/drug therapy
Purpura, Thrombocytopenic, Idiopathic*/chemically induced
Aminopyridines*
Morpholines*
Pyrimidines*
Humans ; Japan ; Pyridines/adverse effects ; Oxazines/adverse effects ; Double-Blind Method ; Treatment Outcome
Raport
Tytuł:
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage.
Autorzy:
Wang Y; National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, 2699 Qianjin Street, Changchun City, Jilin Province, China.
Lin X; Department of Thoracic Surgery, the First Hospital of Jilin University, Changchun, China.
Wang Y; Department of Pediatric Hematology, the First Hospital of Jilin University, 1 Xinmin Street, Changchun City, Jilin Province, China. wang_.
Wang G; National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, 2699 Qianjin Street, Changchun City, Jilin Province, China. .
Pokaż więcej
Źródło:
Investigational new drugs [Invest New Drugs] 2024 Feb; Vol. 42 (1), pp. 70-79. Date of Electronic Publication: 2023 Dec 12.
Typ publikacji:
Journal Article
MeSH Terms:
Pyrimidinones*
Leukemia, Myeloid, Acute*/drug therapy
Morpholines*
Pyrazoles*
Pyrimidines*
Sulfur Compounds*
Humans ; DNA Damage
Czasopismo naukowe
Tytuł:
Regulatory T-cell dysfunctions are associated with increase in tumor necrosis factor α in autoimmune hemolytic anemia and participate in Th17 polarization.
Autorzy:
Ciudad M; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Ouandji S; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Lamarthée B; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Cladière C; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Ghesquière T; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Nivet M; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Thébault M; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Boidot R; Unit of Molecular Biology, Georges-François Leclerc Cancer Center - F-21000 Dijon.
Soudry-Faure A; Department of Clinical Research and Innovation (DRCI), Clinical Research Unit-Methodological Support Network (USMR), Dijon Bourgogne University Hospital, Dijon.
Chevrier S; Unit of Molecular Biology, Georges-François Leclerc Cancer Center - F-21000 Dijon.
Richard C; Unit of Molecular Biology, Georges-François Leclerc Cancer Center - F-21000 Dijon.
Maillet T; Department of Internal Medicine - Centre Hospitalier de Mâcon, Groupe Hospitalier Bourgogne Méridionale - F-71000 Macon.
Maurier F; Department of Internal Medicine, Groupe Hospitalier UNEOS - F-57000 Metz.
Greigert H; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Genet C; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Ramon A; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Trad M; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Predan V; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon.
Saas P; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Samson M; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Bonnotte B; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
Audia S; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon. .
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2024 Feb 01; Vol. 109 (2), pp. 444-457. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
T-Lymphocytes, Regulatory*
Anemia, Hemolytic, Autoimmune*
Aminopyridines*
Morpholines*
Pyrimidines*
Animals ; Humans ; Tumor Necrosis Factor-alpha ; Forkhead Transcription Factors/metabolism ; Th17 Cells
Czasopismo naukowe
Tytuł:
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
Autorzy:
Bosch F; Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address: .
Kuruvilla J; Princess Margaret Cancer Centre, Toronto, ON, Canada.
Vassilakopoulos TP; Department of Haematology and Bone Marrow Transplantation, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Maio DD; F. Hoffmann-La Roche, Basel, Switzerland.
Wei MC; Genentech, South San Francisco, CA.
Zumofen MB; F. Hoffmann-La Roche, Basel, Switzerland.
Nastoupil LJ; The University of Texas MD Anderson Cancer Center, Houston, TX.
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Feb; Vol. 24 (2), pp. 105-121. Date of Electronic Publication: 2023 Sep 28.
Typ publikacji:
Systematic Review; Journal Article
MeSH Terms:
Lymphoma, Follicular*/drug therapy
Antineoplastic Agents*/therapeutic use
Antibodies, Bispecific*/therapeutic use
Benzamides*
Biphenyl Compounds*
Morpholines*
Pyridones*
Humans ; Phosphatidylinositol 3-Kinases ; Neoplasm Recurrence, Local/drug therapy
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies